Vandekop Amy O'Leary reported grant involving 10,000 derivative units of Kalaris Therapeutics, Inc. at $0.00 for $0 on Aug 27, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
VP, Corporate Controller
VP, Corporate Controller
Filed Aug 28, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
10,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
10,000Direct
Trade date
Aug 27, 2026Grant
Filed
Aug 28, 2026, 4:10 PM ET1-day reporting delay
Accession
0001193125-26-374352Code A · Transaction 117328
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

KLRS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KLRS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −3.2%30d −28%90d180d1y

Footnotes in full

F1: The option was granted on August 27, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.